A highly sensitive test that detects traces of disease in the bone marrow of patients with a rare and aggressive type of blood cancer could help double their chances of survival, a first-of-its-kind trial has found.
The 10-minute procedure – which involves an injection in the hip bone every three months – identified signs of acute myeloid leukaemia (AML) returning in patients before it showed in blood tests.
